ArticleRheumatology (Oxford, England)2022
A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG-PET/CT: a Chinese cohort study.
Article in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Amygdalar metabolic activity associated with cerebrovascular events and carotid-vertebral artery stenosis in takayasu arteritis.European journal of nuclear medicine and molecular imaging · 2026Article
- Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026Review
- A new predictor of disease activity in Takayasu's arteritis patients: pericarotid fat density.BMC medical imaging · 2025Article
- Childhood-onset Takayasu arteritis: clinical presentation, challenges and disease course.Pediatric rheumatology online journal · 2025Article
- Association of PET vascular activity score with Takayasu's arteritis angiographic progression.European journal of nuclear medicine and molecular imaging · 2025Observational
- Positron Emission Tomography in Takayasu Arteritis: A Review Including Patterns of Vascular Involvement Across Modalities and Regions.Journal of clinical medicine · 2025Review
- Article
- Metabolic inflammatory volume and total inflammatory glycolysis: novel parameters to evaluate PET-CT disease activity in Takayasu arteritis.Clinical rheumatology · 2023Article
- 18-Fluorodeoxyglucose positron emission tomography/computed tomography for large vessel vasculitis in clinical practice.Frontiers in medicine · 2023Review
- Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis.Diagnostics (Basel, Switzerland) · 2022Review
- Comment on: A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG PET/CT: a Chinese cohort study.Rheumatology (Oxford, England) · 2022Article
- Advances in Takayasu arteritis: An Asia Pacific perspective.Frontiers in medicine · 2022Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in assessing disease activity in Takayasu arteritis (TA).
methodsNinety-one patients with TA were recruited from a Chinese cohort. Clinical data, acute-phase reactants and 18F-FDG-PET/CT findings were simultaneously recorded. The value of using 18F-FDG-PET/CT to identify active disease was evaluated, using ESR as a reference. Disease activity assessment models were constructed and concordance index (C-index), net reclassification index (NRI), and integrated discrimination index (IDI) were evaluated to compare the benefits of the new modes with ESR and the Kerr score.
resultsIn total, 64 (70.3%) cases showed active disease. Higher levels of ESR and CRP, and lower IL-2 receptor (IL-2R) levels were observed in active cases. 18F-FDG-PET/CT parameters measured by determining the standard uptake value (SUV), including SUVmean, SUVratio1, SUVratio2, sum of SUVmean and sum of SUVmax, were significantly higher in active disease groups. The C-index threshold of ESR to indicate active disease was 0.78 (95% CI: 0.69, 0.88). The new activity assessment model combining ESR, sum of SUVmean and IL-2R showed significant improvement in C-index over the ESR method (0.96 vs 0.78, P < 0.01; NRI 1.63, P < 0.01; and IDI 0.48, P < 0.01). The new model also demonstrated modest superiority to the Kerr score assessment (0.96 vs 0.87, P = 0.03; NRI 1.19, P < 0.01; and IDI 0.33, P < 0.01).
conclusionsA novel 18F-FDG-PET/CT-based method that involves combining the sum of SUVmean with ESR score and IL-2R levels demonstrated superiority in identifying active TA compared with conventional methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.